# Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer

> **NCT03727867** · PHASE3 · UNKNOWN · sponsor: **Haihua Yang** · enrollment: 300 (estimated)

## Conditions studied

- Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
- **DEVICE:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT03727867
- **Lead sponsor:** Haihua Yang
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2021-06-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2019-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03727867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03727867, "Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03727867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*